Clinical Trial Update: Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 data on QEL-001 in A2-mismatch liver transplant patients show safety and preliminary clinical activity in the setting of transplant rejection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Diseases
• Liver Failure
• Liver Transplant Rejection

Drugs mentioned

• QEL-001

Snippet

Sponsor: Quell Therapeutics Limited | Conditions: Rejection; Transplant, Liver, Liver Failure | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING